Kirkland Represents Bristol-Myers Squibb on $90B Acquisition of Celgene Corporation
Kirkland & Ellis LLP advised Bristol-Myers Squibb Company (NYSE: BMY) on its agreement to acquire Celgene Corporation (NASDAQ: CELG) in a cash and stock transaction for an enterprise value of $90 billion.
The combined company will have nine products with more than $1 billion in annual sales and significant potential for growth in the core disease areas of oncology, immunology and inflammation, and cardiovascular disease.
The
Team
All Bios
Daniel E. Wolf, P.C. Mergers & Acquisitions / Private Equity
Sophia Hudson, P.C. Capital Markets
Jonathan L. Davis, P.C. Mergers & Acquisitions / Private Equity
Ryan K. Brissette, P.C. Mergers & Acquisitions / Private Equity
David Fox
Linda K. Myers, P.C. Debt Finance
Matthew J. Reilly, P.C. Antitrust & Competition
Dean S. Shulman, P.C. Tax
Sara B. Zablotney, P.C. Tax
Scott D. Price, P.C. Executive Compensation
M.D., Chairman and Chief Executive Officer of Bristol-Myers Squibb…we are creating an innovative biopharma leader, with leading franchises and a deep and broad pipeline that will drive sustainable growth and deliver new options for patients across a range of serious diseases.
Related
- Kirkland Represents Cloverleaf Cold Storage and Blackstone in Merger with Zero Mountain, Inc.
- Global and Regional M&A Reports 2018
- Kirkland’s New Dallas Office Closes Two Energy Deals This Week With Combined Value of Nearly $2 Billion
- Kirkland Counsels Discovery II on $1B Commitment from Stonepeak
- Kirkland Represents Pelican Energy Partners on Investment in Axon Pressure Products